Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 7/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25459923 | 0.85 | TSHR (0.47) | TSHRKDM4EHTTMAOACISD1 | |
| SCHEMBL12601239 | 0.82 | TSHR (0.52) | TSHRKDM4EHTTMAOACISD1 | |
| SCHEMBL264929 | 0.76 | — | — | |
| SCHEMBL16924077 | 0.76 | — | — | |
| SCHEMBL29337016 | 0.74 | EPHX2 (0.44) | TSHRKDM4EHTTMAOACISD1 | |
| SCHEMBL22623764 | 0.72 | TSHR (0.53) | TSHRKDM4EHTTMAOACISD1 | |
| SCHEMBL11169825 | 0.72 | TSHR (0.53) | TSHRKDM4EHTTMAOACISD1 | |
| SCHEMBL11172424 | 0.71 | TSHR (0.52) | TSHRKDM4EHTTMAOACISD1 | |
| SCHEMBL20150476 | 0.68 | TSHR (0.48) | TSHRKDM4EHTTMAOACISD1 | |
| SCHEMBL4859372 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | TSHR 2973/4885KDM4E 4001/4885HTT 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.